CELU
Celularity Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.72
−6.01%Year over year
Reported trailing growth
- Revenue
- -51.0%
- EBITDA
- -86.2%
- EBIT
- -59.8%
- EPS
- -39.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +13.9%
- EBITDA
- -77.7%
- EBIT
- -59.8%
- Net income
- -58.6%
- EPS
- -35.7%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025